These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 30851121)
1. Major Clinical Trials Failed the Amyloid Hypothesis of Alzheimer's Disease. Huang YM; Shen J; Zhao HL J Am Geriatr Soc; 2019 Apr; 67(4):841-844. PubMed ID: 30851121 [No Abstract] [Full Text] [Related]
2. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. Hardy J J Neurochem; 2009 Aug; 110(4):1129-34. PubMed ID: 19457065 [TBL] [Abstract][Full Text] [Related]
3. Why Amyloid Is Still a Target for Alzheimer Disease Clinical Trials. McDade E J Am Geriatr Soc; 2019 Apr; 67(4):845-847. PubMed ID: 30851119 [No Abstract] [Full Text] [Related]
4. Why are drug trials in Alzheimer's disease failing? Smith AD Lancet; 2010 Oct; 376(9751):1466. PubMed ID: 21036274 [No Abstract] [Full Text] [Related]
5. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Karran E; Mercken M; De Strooper B Nat Rev Drug Discov; 2011 Aug; 10(9):698-712. PubMed ID: 21852788 [TBL] [Abstract][Full Text] [Related]
6. Will anti-amyloid therapies work for Alzheimer's disease? St George-Hyslop PH; Morris JC Lancet; 2008 Jul; 372(9634):180-2. PubMed ID: 18640437 [No Abstract] [Full Text] [Related]
7. Alzheimer's disease: expedition into the unknown. The Lancet Lancet; 2016 Dec; 388(10061):2713. PubMed ID: 27924761 [No Abstract] [Full Text] [Related]
8. Alzheimer's disease amyloid hypothesis at crossroads: where do we go from here? Saxena U Expert Opin Ther Targets; 2010 Dec; 14(12):1273-7. PubMed ID: 21058918 [TBL] [Abstract][Full Text] [Related]
9. Do We Need Anti-Prion Compounds to Treat Alzheimer's Disease? Willbold D; Kutzsche J Molecules; 2019 Jun; 24(12):. PubMed ID: 31208037 [TBL] [Abstract][Full Text] [Related]
10. Therapies for Alzheimer's disease. Melnikova I Nat Rev Drug Discov; 2007 May; 6(5):341-2. PubMed ID: 17539055 [No Abstract] [Full Text] [Related]
11. Antibody drugs for Alzheimer's show glimmers of promise. Reardon S Nature; 2015 Jul; 523(7562):509-10. PubMed ID: 26223602 [No Abstract] [Full Text] [Related]
12. A good marker does not mean a good target for clinical trials in Alzheimer's disease: the amyloid hypothesis questioned. Modrego P; Lobo A Neurodegener Dis Manag; 2019 Jun; 9(3):119-121. PubMed ID: 31116074 [No Abstract] [Full Text] [Related]
13. Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease. Lansbury PT Curr Opin Chem Biol; 1997 Aug; 1(2):260-7. PubMed ID: 9667848 [TBL] [Abstract][Full Text] [Related]
14. Biogen's aducanumab raises hope that Alzheimer's can be treated at its source. Patel KR Manag Care; 2015 Jun; 24(6):19. PubMed ID: 26182718 [No Abstract] [Full Text] [Related]
15. Toward an integrated discovery and development program in Alzheimer's disease: the amyloid hypothesis. Greenberg BD; Murphy MF Neurobiol Aging; 1994; 15 Suppl 2():S105-9. PubMed ID: 7700430 [No Abstract] [Full Text] [Related]
16. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. Laske C N Engl J Med; 2014 Apr; 370(15):1459. PubMed ID: 24716688 [No Abstract] [Full Text] [Related]
17. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. Salloway S; Sperling R; Brashear HR N Engl J Med; 2014 Apr; 370(15):1460. PubMed ID: 24724181 [No Abstract] [Full Text] [Related]
18. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. de la Torre JC N Engl J Med; 2014 Apr; 370(15):1459-60. PubMed ID: 24716689 [No Abstract] [Full Text] [Related]
19. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies. Rygiel K Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098 [TBL] [Abstract][Full Text] [Related]